Psoriatic Arthritis
Psoriatic Arthritis
Advertisement
Rob DillardPsoriatic Arthritis | May 15, 2023
Soumya Chakravarty, MD, PhD, FACP, FACR, Senior Director, Strategic Lead, Rheumatology Therapeutic Area at The Janssen ...
View More
Patrick DalyPsoriatic Arthritis | April 10, 2023
In a recent article, investigators described their post hoc analysis of DISCOVER-2, a phase 3 randomized controlled ...
Patrick DalyPsoriatic Arthritis | April 10, 2023
Researchers, led by Gerd R Burmester, conducted a clinical trial to evaluate the long-term safety outcomes of ...
Patrick DalyPsoriasis | April 12, 2023
Psoriatic arthritis (PsA) is an inflammatory disease that commonly affects patients with psoriasis. According to a study ...
Rebecca AraujoPsoriatic Arthritis | April 10, 2023
Ixekizumab demonstrated favorable tolerability and safety, in line with previous reports, for treatment of psoriatic ...
Kaitlyn D’OnofrioPsoriasis | April 12, 2023
In a recent study, researchers compared ustekinumab versus other biologics and apremilast for risk of serious infection ...
Kaitlyn D’OnofrioPsoriasis | April 12, 2023
Early identification of certain patient factors may predict long-term outcomes in psoriasis, according to a study. ...
Kaitlyn D’OnofrioPsoriatic Arthritis | April 10, 2023
A study retrospectively compared rates of treatment retention with golimumab among patients with rheumatoid arthritis ...
Kaitlyn D’OnofrioPsoriatic Arthritis | April 10, 2023
Guselkumab was a safe and effective treatment for biologic-naïve patients with psoriatic arthritis (PsA), according to ...
Kaitlyn D’OnofrioPsoriatic Arthritis | April 10, 2023
Patients with psoriatic arthritis (PsA) who achieved minimal disease activity on ixekizumab may relapse if they ...
Kaitlyn D’OnofrioPsoriasis | May 2, 2023
An analysis of two studies comparing adalimumab biosimilar SDZ-ADL versus reference adalimumab in patient-reported ...
Kaitlyn D’OnofrioDepression | April 10, 2023
A recent study analyzed the prevalence of and factors associated with sleep disturbances, fatigue, and ...
Kaitlyn D’OnofrioPsoriatic Arthritis | April 10, 2023
Inflammatory arthritis (IA) patients often experience fatigue; 41% to 51% of rheumatoid arthritis (RA), psoriatic ...
Kaitlyn D’OnofrioPsoriatic Arthritis | April 10, 2023
A study ascertained the effect of joint and skin symptoms on psoriatic arthritis (PsA) patients and found that they ...
DocWire News EditorsPsoriatic Arthritis | April 10, 2023
Early psoriatic arthritis detection can pose a challenge for rheumatologists—especially in the presence of psoriasis. ...
Kaitlyn D’OnofrioPsoriatic Arthritis | April 10, 2023
The randomized, double-blind BE ACTIVE trial compared bimekizumab versus placebo in patients with active psoriatic ...
Kaitlyn D’OnofrioPsoriatic Arthritis | April 10, 2023
A new study evaluated healthcare utilization among psoriatic arthritis (PsA) patients in the years leading up to their ...
Kaitlyn D’OnofrioPsoriatic Arthritis | April 10, 2023
Patients with psoriatic arthritis (PsA) may observe improved long-term outcomes with secukinumab treatment, according to ...
Kaitlyn D’OnofrioPsoriatic Arthritis | April 10, 2023
A study recently published in Annals of the Rheumatic Diseases found that ixekizumab may be superior to adalimumab in ...
Kaitlyn D’OnofrioPsoriasis | April 12, 2023
Pediatric psoriasis patients have a higher risk of other comorbidities—including psychiatric disorders—than their ...
Advertisement
Advertisement
Advertisement
Latest News

February 23, 2024